Perrigo Stock (NYSE:PRGO)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$9.81

52W Range

$9.24 - $29.08

50D Avg

$13.83

200D Avg

$19.68

Market Cap

$1.30B

Avg Vol (3M)

$3.44M

Beta

0.41

Div Yield

$1.16 (12.31%)

PRGO Company Profile


Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees brand names. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 23 countries, primarily in Europe. The company also offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

IE

Employees

8,379

IPO Date

Dec 17, 1991

Website

PRGO Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
Consumer Self-Care International$1.67B$1.68B-
Consumer Self-Care Americas$2.59B$2.69B-
Contract Manufacturing--$337.30M

Fiscal year ends in Dec 25 | Currency in USD

PRGO Financial Summary


Dec 25Dec 24Dec 23
Revenue$4.25B$4.37B$4.66B
Operating Income$-1.12B$112.90M$151.90M
Net Income$-1.43B$-171.80M$-12.70M
EBITDA$-1.12B$433.00M$525.00M
Basic EPS$-10.29$-1.25$-0.09
Diluted EPS$-10.29$-1.25$-0.09

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q4 25Feb 26, 26 | 8:30 AM
Q3 25Nov 05, 25 | 8:30 AM
Q2 25Aug 06, 25 | 8:30 AM

Peer Comparison


TickerCompany
HTFLHeartflow, Inc. Common Stock
HCMHUTCHMED (China) Limited
BHCBausch Health Companies Inc.
ATECAlphatec Holdings, Inc.
FOLDAmicus Therapeutics, Inc.
SUPNSupernus Pharmaceuticals, Inc.
TARSTarsus Pharmaceuticals, Inc.
SGRYSurgery Partners, Inc.
LIVNLivaNova PLC
SRRKScholar Rock Holding Corporation